A Research Guide for
SMA

A positive newborn screen for SMA is a neurogenetic emergency — especially for babies with 2 SMN2 copies, who can develop irreversible motor neuron loss within weeks. Expect the following sequence, usually within days:

1. Urgent referral to a pediatric neurologist or neuromuscular specialist (in Utah, typically Primary Children’s Hospital or the University of Utah).
2. Confirmatory testing — A second blood sample is sent for definitive SMN1/SMN2 analysis, often through ARUP Laboratories in Salt Lake City.
3. Baseline assessment — Motor exam (CHOP-INTEND for infants), breathing assessment, swallow evaluation, and bloodwork.
4. Treatment decision — Family meeting with the neuromuscular team to choose among Zolgensma, Spinraza, and Evrysdi based on SMN2 copy number, weight, anti-AAV9 antibody status (for Zolgensma), and family values.
5. Treatment initiation — Ideally within the first 2–6 weeks of life for babies with 2–3 SMN2 copies.

This pace can feel disorienting. Bringing a notebook, a second listener, and a list of questions to each appointment helps.

Not everyone with SMA is diagnosed as a newborn. Symptoms that prompt testing later include:

• An infant or toddler not meeting motor milestones (delayed sitting, not walking by 15–18 months)
• A school-age child with progressive weakness, frequent falls, or trouble climbing stairs
• A teen or adult with unexplained proximal weakness (thighs, hips, shoulders), muscle twitching (fasciculations), or hand tremor

Adult diagnosis often takes years because SMA Type 3 and Type 4 can look like other neuromuscular conditions. If you have unexplained proximal weakness, ask whether SMN1/SMN2 testing has been done — it’s a simple blood test, and treatment is available for adults.

If your child is diagnosed with SMA, both parents are carriers. Each future pregnancy carries a 1 in 4 chance of having SMA, a 1 in 2 chance of being an unaffected carrier, and a 1 in 4 chance of inheriting two normal copies. Genetic counseling can help with:

• Understanding inheritance for siblings and extended family
• Carrier testing for adult siblings, aunts, uncles, and cousins who may be planning families
• Prenatal testing options (chorionic villus sampling, amniocentesis) in future pregnancies
• Preimplantation genetic testing (PGT) with IVF to select unaffected embryos
• Emotional support for the implications of carrier status

• How many SMN2 copies does my child have, and what does that mean for what to expect?
• Was the SMN1 result a deletion of both copies, or one deletion and one mutation? Does that matter for treatment?
• Should I be tested? Should my partner? Other relatives?
• If we want more children, what are our options for prenatal or preimplantation testing?
• Will I get a written copy of the genetic test results to keep?
• Is there a research registry (like Cure SMA or TREAT-NMD) we can join?

What it is: A one-time intravenous (IV) infusion that delivers a working copy of the SMN1 gene to motor neurons using an inactivated virus (AAV9) as a carrier. The infusion takes about an hour.

Who it’s for: Children under 2 years old with SMA. Most often used in babies under about 13.5 kg (the weight at which most centers stop offering it). Pre-treatment testing checks for anti-AAV9 antibodies that would block the therapy.

What to expect afterward:

• An oral steroid (prednisolone) is given before the infusion and continued for at least 2 months, then tapered, to manage immune response and protect the liver.
• Weekly bloodwork for at least the first month to monitor liver enzymes, platelets, and kidney markers.
• Strict avoidance of live vaccines during steroid treatment.
• Rare but serious risks include liver injury, low platelet counts (which can affect bleeding), and a rare blood clotting disorder called thrombotic microangiopathy (TMA). Serious liver injury is the basis of Zolgensma's FDA boxed warning (its most serious warning) — acute liver failure, including rare deaths, has been reported — which is why the steroid and the close liver-enzyme monitoring above are essential.

Cost: List price near $2.1 million per dose in the U.S. — the highest list price of any approved drug. It is usually covered by insurance for eligible patients, but the prior authorization process is intensive.

Long-term data: Five-year follow-up from the original Zolgensma trials shows that motor function gains are sustained in most children, and many pre-symptomatically treated children are walking independently.

What it is: The same SMN1 gene therapy as Zolgensma, but delivered intrathecally (into the spinal fluid by lumbar puncture) instead of by IV infusion. The intrathecal route lets the therapy reach motor neurons effectively in larger, older patients, for whom the IV dose is impractical.

Who it’s for: Children 2 years and older, teens, and adults with SMA (confirmed SMN1 mutation). It is the first and only one-time gene replacement therapy approved for this broader, older population — previously, gene therapy was limited to infants under 2 years (IV Zolgensma). It uses a fixed dose that does not need adjustment for age or weight.

Regulatory status: FDA-approved on November 24, 2025 (Novartis). Pre-treatment testing for anti-AAV9 antibodies still applies, as with IV gene therapy.

What to expect: As with other AAV9 gene therapies, an oral steroid is given around the time of treatment and monitoring for liver enzymes, platelets, and signs of thrombotic microangiopathy is required. The intrathecal procedure is performed by clinicians experienced with lumbar puncture; severe scoliosis or spinal fusion may require image guidance.

This is a newly approved option — discuss eligibility, anti-AAV9 antibody status, and how it compares with Spinraza and Evrysdi with your SMA specialist.

What it is: An antisense oligonucleotide (ASO) — a small piece of synthetic genetic material — that nudges the SMN2 gene to produce more functional SMN protein. It is given directly into the fluid around the spinal cord by lumbar puncture (spinal tap).

Dosing schedule: Four loading doses over about two months, then a maintenance dose every 4 months for life. A new higher-dose regimen was FDA-approved in March 2026 (two 50 mg loading doses two weeks apart, then 28 mg every 4 months) based on the DEVOTE study; people already on the original 12 mg dose can switch with a single higher dose. Ask your neurologist whether the higher-dose schedule is right for you.

Who it’s for: All ages, all types of SMA. It is the only therapy with the broadest age range, including adults.

What to expect:

• Each dose requires a clinic visit, sometimes with sedation for young children.
• In children and adults with severe scoliosis or spinal fusion, the lumbar puncture may need to be done with CT or ultrasound guidance, sometimes through a special spinal approach.
• Side effects are usually mild — headache, back pain after the procedure. Long-term safety is well-established with over a decade of clinical experience.

Cost: Approximately $750,000 in the first year (loading doses), then $375,000 per year for maintenance, before negotiated discounts.

Long-term data: Extensive real-world data, including in adults, shows sustained motor stability or improvement and excellent safety over many years.

What it is: An oral liquid medication that, like Spinraza, modifies SMN2 to produce more SMN protein. Unlike the other two therapies, it reaches the entire body — not just motor neurons — and is taken daily at home.

Who it’s for: Adults and children with SMA, including infants from birth.

What to expect:

• Dosed by weight and age, given once daily as a liquid (usually mixed with a small amount of food or water).
• No procedures, no infusions, no clinic visits for administration.
• Common side effects: diarrhea, fever, rash, mouth ulcers. Most are mild.
• Requires a specialty pharmacy and refrigerated storage in some forms.
• Drug interaction warnings exist for some medications — always tell every prescriber that your child or you take risdiplam.
• Pregnancy precautions apply: both men and women of reproductive age should discuss contraception, because risdiplam may affect fertility and fetal development.

Cost: Approximately $340,000 per year for adults (weight-dependent), before negotiated discounts.

Long-term data: The SUNFISH and FIREFISH trials and their long-term extensions show sustained motor improvement or stability in patients across SMA types and ages.

There is no universal “best” therapy. The decision typically weighs:

• Age and weight — IV Zolgensma is typically restricted to children under 2 and roughly under 13.5 kg. Since November 2025, the intrathecal version (Itvisma) extends one-time gene therapy to patients 2 years and older, including teens and adults.
• Anti-AAV9 antibody status — If a child has antibodies against the AAV9 virus used in Zolgensma, gene therapy is not an option.
• Spinal anatomy — Severe scoliosis or spinal fusion can make Spinraza injections technically challenging.
• Travel and logistics — Spinraza requires clinic visits every 4 months; Evrysdi is daily at home; Zolgensma is one-time.
• Family preference — Some families prefer the “one and done” nature of gene therapy; others prefer the long track record of Spinraza or the convenience of Evrysdi.
• Insurance coverage — Each insurer has different prior authorization criteria for each therapy.

Some families ultimately use combination therapy — for example, Zolgensma followed by Spinraza or Evrysdi. This is increasingly common but remains off-label and should be discussed thoroughly with your specialist.

The SMA treatment landscape is rapidly evolving. Important investigational agents to know about:

• Apitegromab — A monoclonal antibody that targets myostatin (a protein that limits muscle growth) to strengthen muscle directly, used in addition to an SMN-targeted therapy. The Phase 3 SAPPHIRE trial in non-ambulatory children and adults with SMA Type 2 or 3 met its primary endpoint of improved motor function. As of May 2026, apitegromab is not yet FDA-approved: the FDA issued a Complete Response Letter in September 2025 related to manufacturing facility observations (not safety or efficacy), and Scholar Rock resubmitted the application in March 2026. U.S. and European launches are anticipated in 2026 if approval is granted.
• Combination therapy — Real-world use of Zolgensma followed by Spinraza or Evrysdi is expanding, with growing safety and efficacy data.
• Next-generation gene therapies — Several biotech companies are developing AAV-based gene therapies designed for older or heavier patients, and intrathecal delivery approaches that could expand access beyond Zolgensma’s current age and weight limits.
• SMN-independent strategies — Therapies targeting downstream consequences of motor neuron disease, including muscle and neuromuscular junction interventions, are in earlier trials.

Talk to your specialist about ongoing clinical trials — participation can be an option for some patients.

• Given my child’s age, weight, and SMN2 copy number, which therapies are options?
• What are the chances my child has anti-AAV9 antibodies, and when will that be tested?
• How quickly do we need to choose — and start — treatment?
• What are the realistic motor expectations with each therapy?
• Is combination therapy something we should discuss now, or revisit later?
• Are there clinical trials we should consider?
• If apitegromab is approved later this year, how would it fit in?

• Olesoxime (Roche/Trophos) — A cholesterol-like neuroprotective compound that showed promise in a Phase 2 trial but failed to demonstrate meaningful motor function improvement in the Phase 2/3 extension study in SMA Types 2 and 3. Roche discontinued development in 2018. FAILED
• Valproic acid and other HDAC inhibitors — Multiple trials of valproic acid, phenylbutyrate, and hydroxyurea tested the hypothesis that histone deacetylase inhibition could upregulate SMN2 expression. Several controlled trials showed no clinically meaningful motor benefit, and valproic acid carries metabolic and hepatic side effects. These are no longer recommended for SMA treatment. DE-ADOPTED
• Creatine — Studied in a placebo-controlled trial for SMA Types 2 and 3. No significant improvement in motor function or pulmonary outcomes. FAILED
• Gabapentin — Tested in SMA Types 2 and 3 in controlled trials. No significant motor benefit demonstrated. FAILED
• Riluzole — Approved for ALS, riluzole was studied in SMA but did not show evidence of motor neuron protection or clinical improvement in SMA patients. FAILED
• Stem cell transplantation (unregulated) — Some families have sought stem cell treatments at overseas clinics not associated with regulated clinical trials. No controlled evidence supports this approach for SMA, and the risks include infection, immune reactions, and financial exploitation. Regulated stem cell research for motor neuron diseases is ongoing but has not yet yielded an approved therapy. WITHDRAWN

Weak respiratory muscles are the leading source of serious complications in SMA. Care typically involves:

• Sleep studies (polysomnography) to look for low oxygen or high carbon dioxide overnight, when respiratory weakness shows up first.
• Non-invasive ventilation (BiPAP) — A small mask worn at night that supports breathing without a breathing tube. Often the first major respiratory intervention.
• Cough assist devices — Help clear secretions from the lungs when the natural cough is too weak. Critical during respiratory infections.
• Suction machines at home for managing oral secretions.
• Vaccinations — RSV prophylaxis (palivizumab or nirsevimab for eligible infants), influenza, COVID-19, and pneumococcal vaccines are especially important.
• Tracheostomy and long-term ventilation — In severe cases, especially historically untreated SMA Type 1, an extended decision-making conversation. Less commonly needed in pre-symptomatically treated children today.

Many families learn to use the cough assist and BiPAP themselves at home. The respiratory therapist who trains you is one of the most important members of your team.

Weakness can make feeding difficult, increase the risk of choking and aspiration (food or liquid going into the lungs), and lead to either undernutrition or, in less mobile children, excess weight gain. Expect ongoing involvement of:

• Speech and swallow therapists — Evaluate the safety of eating by mouth and recommend feeding strategies.
• Dietitians — Track growth and adjust calorie, protein, and micronutrient targets. Children with SMA often have unusual body composition (less muscle, sometimes more fat for their weight).
• Gastrostomy tube (G-tube) decisions — A small feeding tube placed through the abdomen into the stomach can be life-changing for children who cannot eat enough safely by mouth. This does not have to be permanent and is often reversible if feeding skills improve.
• Bone health — Vitamin D, calcium, and (in some cases) bisphosphonate treatments to reduce fracture risk, which is elevated in SMA.

Without normal muscle pull, bones and joints develop differently. The orthopedic team monitors and treats:

• Scoliosis — Sideways curvature of the spine. Common in non-ambulatory children. Treatment ranges from bracing to growing rods (in young children) to spinal fusion (typically after age 10–12). The era of SMN-targeted therapy is changing scoliosis trajectories — many treated children develop milder curves later than historical cohorts.
• Hip subluxation and dislocation — Especially in non-walkers. Often managed conservatively unless painful.
• Contractures — Tightness of joints from limited movement. Stretching, splinting, and (rarely) surgery can help.
• Custom seating — A properly fitted wheelchair or seating system is not just about mobility; it’s about spinal alignment, breathing, comfort, and skin health.

Children with severe scoliosis or spinal fusion who need ongoing Spinraza may require special imaging or alternative approaches for intrathecal injections. This is one of the key practical considerations in long-term therapy planning.

PT and OT are the through-line of life with SMA. The goals shift over time:

• In infants and toddlers — Encouraging head control, sitting, transitions, and exploration. Pre-symptomatically treated babies may pursue typical milestones.
• In school-age children — Maintaining strength, optimizing function, supporting transitions between sitting, standing, and walking (with or without assistive devices).
• In teens and adults — Preserving independence, energy conservation, adaptive equipment, fall prevention, exercise tailored to fatigue and respiratory limits.

Aquatic therapy can be especially helpful — the buoyancy of water lets people move in ways that aren’t possible on land.

• When should we have our first sleep study? How often after that?
• Do we have the right cough assist and suction equipment, and is everyone in the household trained on it?
• Is my child’s growth on track for someone with SMA, or are we under- or over-feeding?
• When should we expect to discuss a G-tube, if ever?
• How is the spine looking? Do we need a brace? When will we consider surgery?
• What does an ideal PT/OT schedule look like for us right now?
• If we live far from a specialty center, can some of this care happen locally?

Children with SMA almost always qualify for school accommodations under the Individuals with Disabilities Education Act (IDEA, via an Individualized Education Plan or IEP) or Section 504 of the Rehabilitation Act. Common supports:

• Accessible classrooms and bathrooms
• Personal care attendants
• Adapted physical education
• Accessible technology and seating
• Excused absences for clinic visits and medical care
• Adapted transportation
• Modified gym, recess, and field-trip plans

Many parents recommend requesting an IEP evaluation before kindergarten and revisiting it annually. School districts in Utah and elsewhere have specialists who handle complex medical IEPs; ask the district directly.

The financial side of SMA is often as taxing as the medical side. Practical advice from families who have been through it:

• Get a hospital social worker and a financial navigator early. Most academic neuromuscular centers have one assigned to SMA families.
• Manufacturer patient assistance programs — Each of Zolgensma (Novartis), Spinraza (Biogen), and Evrysdi (Genentech) has a dedicated patient support program with case managers.
• Specialty pharmacies handle high-cost drugs differently than retail pharmacies; expect a learning curve.
• Medicaid waivers — Many states, including Utah, have waivers that provide additional support to children with significant disabilities regardless of household income. Eligibility rules are complex; a social worker can guide you.
• Out-of-pocket maximums — Once met for the year, additional covered care is paid 100% by insurance. This affects timing of major procedures.
• Document everything. Keep a folder with all insurance correspondence, EOBs (Explanation of Benefits), and prior authorization letters.

One of the newer challenges in SMA is what happens after a child outgrows pediatric neurology. Adult neuromuscular medicine is a smaller specialty, and not every adult neurologist is comfortable managing the long-term complications of SMA. Tips:

• Start the transition conversation by age 14–16, not at 18.
• Ask your pediatric team for an adult neuromuscular referral well in advance.
• The MDA Care Center model at academic centers (including the University of Utah) sees both children and adults.
• Keep all genetic test results, prior authorization letters, motor function scores (CHOP-INTEND, HFMSE, RULM), and imaging in your possession.

SMA is a marathon for everyone in the family. Topics that come up over the years:

• Anxiety and depression in older children, teens, and adults with SMA
• Sibling experience — brothers and sisters of children with significant medical needs benefit from their own outlets and time
• Marital strain in parents of medically complex children — couples therapy is not a sign of failure
• Grief that doesn’t fit traditional categories — for the path that wasn’t taken, even when the current path is going well
• Identity in young adults with SMA — disability identity, dating, work, independence

Most major neuromuscular clinics have psychologists or social workers experienced with SMA families. Cure SMA also offers peer-support networks that families consistently rate as one of the most valuable resources.

• Does our center have a social worker, financial navigator, or family liaison?
• What Medicaid waivers or state programs might we be eligible for?
• Who handles the transition to adult care, and when should we start?
• Are there local Cure SMA or MDA family events?
• What mental health support is available for me as a caregiver?

• Cure SMA (curesma.org) — The primary U.S. patient advocacy organization. Newly diagnosed family packets, research updates, annual conferences, and chapter events.
• Muscular Dystrophy Association (MDA) (mda.org) — Funds Care Centers (including at the University of Utah), summer camps, equipment loans, and research.
• SMA Europe (sma-europe.eu) — Federation of European SMA patient organizations.
• SMA Foundation (smafoundation.org) — Research-focused.
• TREAT-NMD Neuromuscular Network (treat-nmd.org) — International registry and research consortium.
• SMA REACH (UK-based) — Pediatric SMA natural history and outcomes network.

• University of Utah Neuromuscular Program / MDA Care Center — Multidisciplinary care for children and adults with SMA. The hub for SMN-targeted therapy administration in the Intermountain West.
• Primary Children’s Hospital (Salt Lake City) — Pediatric neuromuscular clinic with respiratory, orthopedic, and rehabilitation services.
• Intermountain Health — Pediatric neurology referral pathways and post-acute services across the region.
• Utah Newborn Screening Program — Utah was the first U.S. state to add SMA to its newborn screen (since January 2018); the program coordinates urgent confirmatory testing and specialist referral.
• ARUP Laboratories (Salt Lake City) — National reference lab for SMN1/SMN2 genetic testing.
• Cure SMA Rocky Mountain Chapter — Regional family events and local support.

It is honest to acknowledge that SMA care looks very different across the world:

• Newborn screening for SMA is universal in the U.S. and Germany; widespread in Australia, Belgium, Taiwan, and Italy; piloting in Japan, the UK, Canada, France, and Korea; and largely unavailable in low- and middle-income countries.
• Zolgensma is reimbursed in fewer than half the countries where SMA care exists; some countries have used managed-access “lottery” programs.
• Spinraza and Evrysdi have broader access through various reimbursement agreements, but in many regions only specific SMA types or ages qualify.
• Intrathecal infrastructure for Spinraza is limited in some areas, particularly outside major cities.
• In some Middle Eastern, North African, and South Asian populations with higher consanguinity, SMA prevalence is also higher — making the access gap especially painful.

If you are caring for an international family member with SMA, contact SMA Europe, the regional SMA federation, or TREAT-NMD for region-specific guidance.

Things to track in a notebook or app:

• Medication doses, times, missed doses
• BiPAP and cough assist use
• Weight, height (or arm span if scoliosis is severe)
• Sick days, fevers, hospitalizations
• Motor milestones or changes in function
• Equipment serial numbers and last-service dates

Red flags — call your team or seek care:

• New weakness or loss of a skill that was previously present
• Increased work of breathing, especially at rest or during sleep
• Choking or coughing with feeds, weight loss, or feeding refusal
• Fever with respiratory symptoms in a child with SMA — lower threshold for urgent evaluation than for typical children
• For children on or after Zolgensma: yellowing of the skin or eyes, vomiting, bruising, dark urine
• For anyone on Evrysdi: severe diarrhea, rash, mouth sores

Going-to-the-hospital bag for SMA emergencies:

• Current medication list (with doses and times)
• Copy of the SMA genetic test result
• Recent clinic notes, especially respiratory and motor assessments
• Equipment list (BiPAP settings, cough assist settings)
• Emergency care plan letter from your SMA specialist, if you have one
• Contact information for your neuromuscular team

• Can you write us a one-page emergency care plan for hospital visits?
• Do you participate in Cure SMA or TREAT-NMD registries? Should we?
• Are there clinical trials open at your center we should know about?
• Can we have direct contact information — nurse line, secure messaging — for urgent questions?
• Who can we call after hours if something is concerning but not an emergency?

• SMA (Spinal Muscular Atrophy) — A genetic disorder that causes motor neurons in the spinal cord to break down, leading to progressive muscle weakness and difficulty with movement, breathing, and swallowing.
• SMN1 (Survival Motor Neuron 1) — The primary gene responsible for producing the SMN protein, which motor neurons need to survive. SMA is caused by a missing or non-working copy of this gene.
• SMN2 (Copy Number) — A “backup” gene that makes a small amount of functional SMN protein. People with more copies of SMN2 generally have milder forms of SMA, so copy number helps predict disease severity.
• Motor Neuron — A nerve cell in the brain or spinal cord that sends signals to muscles, telling them to move. In SMA, these cells gradually deteriorate because they lack enough SMN protein.
• NBS (Newborn Screening) — A routine blood test done shortly after birth that can detect SMA before symptoms appear. Early detection allows treatment to begin as soon as possible, which greatly improves outcomes.
• Nusinersen (Spinraza) — The first FDA-approved treatment for SMA. It is an antisense oligonucleotide injected into the spinal fluid that helps the SMN2 gene produce more functional SMN protein.
• Onasemnogene abeparvovec (Zolgensma / Itvisma) — A one-time gene therapy that delivers a working copy of the SMN1 gene into motor neurons using a harmless virus (AAV9) as a delivery vehicle. The original IV formulation (Zolgensma) is for children under two; the intrathecal formulation (Itvisma, FDA-approved November 2025) extends gene therapy to patients 2 years and older.
• Risdiplam (Evrysdi) — An oral liquid medication taken daily at home that helps the SMN2 gene produce more functional SMN protein. It is approved for patients of all ages with SMA.
• AAV9 (Adeno-Associated Virus Serotype 9) — A harmless virus used as a delivery vehicle in Zolgensma gene therapy. It can cross from the bloodstream into the nervous system, carrying a working copy of the SMN1 gene to motor neurons.
• Intrathecal — A method of delivering medication directly into the spinal fluid through a lumbar puncture (spinal tap). Spinraza is given this way to reach the motor neurons in the spinal cord.
• CHOP-INTEND — A clinical assessment scale used to measure motor function in infants with SMA. Higher scores indicate better motor ability, and improvements on this scale help track how well treatment is working.
• HFMSE (Hammersmith Functional Motor Scale Expanded) — A standardized test used to measure motor function in children and adults with SMA who can sit. It evaluates abilities like sitting, rolling, and standing to track disease progression and treatment response.
• Apitegromab — An investigational (not yet approved) antibody therapy being studied as an add-on treatment for SMA. It works by blocking myostatin, a protein that limits muscle growth, with the goal of improving muscle strength beyond what SMN-targeted therapies achieve alone.
• SMA Type 1 — The most severe form of SMA, appearing before six months of age. Without treatment, affected infants cannot sit independently and historically had very limited life expectancy. Early treatment has dramatically changed outcomes.
• SMA Type 2 — An intermediate form of SMA with symptom onset between 6 and 18 months. Children can learn to sit but typically cannot walk independently without treatment. Respiratory and orthopedic care are important parts of management.
• SMA Type 3 — A milder form of SMA with symptom onset after 18 months. Individuals can walk at some point in their lives, though some may lose that ability over time. Life expectancy is generally normal.
• SMA Type 4 — The mildest and rarest form of SMA, with symptom onset in adulthood (usually after age 30). It causes mild to moderate muscle weakness and does not typically affect life expectancy.
• BiPAP (Bilevel Positive Airway Pressure) — A breathing support machine that delivers air pressure through a mask to help keep the airways open. Many people with SMA use BiPAP during sleep or rest to support weakened breathing muscles.
• Cough Assist (Mechanical Insufflation-Exsufflation) — A device that helps clear mucus from the lungs by alternating positive and negative air pressure to simulate a strong cough. It is essential for people with SMA who have weak cough strength.
• Scoliosis — An abnormal sideways curvature of the spine. Scoliosis is very common in SMA due to weak trunk muscles, and it can worsen over time, sometimes requiring bracing or surgery to protect breathing and comfort.
• Bulbar Function — The ability to swallow, chew, speak, and manage saliva, controlled by nerves in the brainstem (bulbar region). Weakness in bulbar function is common in more severe SMA types and may require modified diets or feeding tube support.